GET THE APP
Cancer Science and Pediatrics 2019: Negative prognostic significance of primary cilia, CD8+ tumor infiltrating lymphocytes and PD1+ cells expression in clear cell renal cancer - Josef Dvorak - Charles University and Thomayer Hospital, Czech Republi0063 | Abstract
AgiAl Publishing House

Pediatric Oncology: Open Access

Abstract

About the Journal Abstracting and Indexing Aim and Scope Author Guidelines Article Processing Charges Articles in Process Contact Information Disclosure Policy and Publication Ethics Editorial Board Editorial Workflow Archive
Indexed In
  • Genamics JournalSeek
  • Directory of Open Access Journals
  • Pollution Abstracts
  • Publons
  • International committee of medical journals editors (ICMJE)
  • Google Scholar
  • Chemical Abstract
View More
Awards Nomination

Cancer Science & Pediatrics 2019: Negative prognostic significance of primary cilia, CD8+ tumor infiltrating lymphocytes and PD1+ cells expression in clear cell renal cancer - Josef Dvorak - Charles University and Thomayer Hospital, Czech Republi0063

Author(s): Josef Dvorak

Statement of the Problem: Primary cilia are specialized sensory microtubulebased organelles that project from the surface of almost all human cells except hematopoietic cells. Primary cilia are considered to represent a functional homologue of the immune synapse due to morphological and functional similarities in architecture. The aim of this study was to investigate the potential association and combined prognostic significance of the frequency of primary cilia (PC), programmed cell death protein-1 receptor (PD1) and CD8+ tumor infiltrating lymphocytes (TIL) in patients with clear cell renal cancer (ccRCC). Methods: The frequency of PC, PD1 expression and the frequency of intratumoral CD8+TIL were evaluated in 104 ccRCC patients. Results: The expression of PD1+ cells was <5% in 52 patients, 5-25% in 34 patients and 26-50% in 13 patients and >50% in 5 patients. Intratumoral CD8+ TIL were evaluable in all patients: negative in 1 patient, <25% in 63, 26-50% in 29 and >50% in 11 patients, respectively. Overall survival (OS)

Share this article